Yahoo Finance

ESC Congress 2024: INFINITY-SWEDEHEART Trial of Elixir Medical’s DynamX Bioadaptor Meets Primary Endpoint and Clinical Results Confirm Unique Mechanism of Action

LONDON – September 2, 2024 – Elixir Medical, a developer of disruptive technologies to treat cardiovascular disease, today announced the INFINITY-SWEDEHEART Randomized Controlled Trial (RCT) comparing ...
TCTMD

INFINITY-SWEDEHEART: ‘Unlocking’ Device Bests DES Over Time

SAN FRANCISCO, CA—Use of a novel “unlocking” coronary device is associated with nearly a 50% reduction in the risk of target lesion failure between 6 months and 2 years, according to a landmark ...
Business Wire

Elixir Medical’s DynamX Bioadaptor Demonstrates Significant Improvement Over Contemporary Drug-Eluting Stent in Patients with Acute Coronary Syndrome and Complex Lesion ...

WASHINGTON--(BUSINESS WIRE)--Elixir Medical, a developer of disruptive technologies to treat cardiovascular disease, today announced late-breaking data demonstrating significant benefit of the DynamX ...
TCTMD

‘Unlocking’ Scaffold Matches DES in Wide Range of PCI Patients, Including ACS

LONDON, England—A device designed to deter accruing risks of stent-related adverse events has proven itself once again in a noninferiority trial against a workhorse drug-eluting stent, results from ...
Yahoo Finance

Elixir Medical Completes Enrollment of INFINITY-SWEDEHEART Clinical Trial

-Largest randomized trial of DynamX Bioadaptor to date with 2,400 patients enrolled, covering real-world population- MILPITAS, Calif., July 13, 2023--(BUSINESS WIRE)--Elixir Medical, a developer of ...
The Globe and Mail

Elixir Medical Announces Commencement of INFINITY-SWEDEHEART Randomized Controlled Trial of DynamX Coronary Bioadaptor System

Elixir Medical, a developer of innovative, drug-eluting cardiovascular devices, today announced commencement of the INFINITY-SWEDEHEART randomized controlled trial (RCT) of the DynamX™ Coronary ...
Finanznachrichten

Elixir Medical Corporation: TCT 2024: Elixir Medical to Present Clinical Outcomes on Two Transformative Platforms Designed to Advance Cardiovascular Disease Treatment and ...

Late-breaking INFINITY-SWEDEHEART Randomized Clinical Trial (RCT) data evaluating DynamX Coronary Bioadaptor System's unique mechanism of action among patients with Acute Coronary Syndrome (ACS) and ...
Nature

Bioadaptor implant versus contemporary drug-eluting stent in percutaneous coronary interventions in Sweden (INFINITY-SWEDEHEART): a single-blind, non-inferiority, registry ...

The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...
Hosted on MSN

Stent-Like Hybrid on Track for Lofty Long-Term Goals in PCI

For percutaneous coronary intervention (PCI) on de novo lesions, the DynamX bioadaptor not only matched drug-eluting stents (DES) in early performance but seemed to keep stent-related events from ...
Business Wire

Elixir Medical Completes Enrollment of INFINITY-SWEDEHEART Clinical Trial

MILPITAS, Calif.--(BUSINESS WIRE)--Elixir Medical, a developer of breakthrough cardiovascular technologies, today announced enrollment completion in INFINITY-SWEDEHEART, a prospective, multicenter, ...
Finanznachrichten

Elixir Medical Corporation: Elixir Medical Announces Commencement of INFINITY-SWEDEHEART Randomized Controlled Trial of DynamX Coronary Bioadaptor System

Elixir Medical, a developer of innovative, drug-eluting cardiovascular devices, today announced commencement of the INFINITY-SWEDEHEART randomized controlled trial (RCT) of the DynamX Coronary ...